Suppr超能文献

血液恶性肿瘤患者造血干细胞移植(HSCT)后同伴支持的定性研究。

Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study.

机构信息

Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA.

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Bone Marrow Transplant. 2022 Aug;57(8):1277-1286. doi: 10.1038/s41409-022-01711-9. Epub 2022 May 19.

Abstract

Peer support, a distinctive form of social support in which patients share emotional, social, and practical help based on their own lived experience of illness and treatment, positively impacts patient-reported outcomes in cancer populations. However, data on peer support experiences among hematopoietic stem cell transplant (HSCT) recipients are limited. We conducted semi-structured qualitative interviews among 12 allogeneic HSCT recipients who were ≤6 months post transplant without any complications and 13 allogeneic HSCT recipients >6 months post transplant and living with chronic graft-versus-host disease. Interviews explored patients' experiences with peer support and their preferences for a peer support intervention tailored to the needs of HSCT recipients. While the majority (70%) of participants reported no formal experience with peer support, most (83%) articulated themes of potential benefits of peer support (e.g., managing expectations and uncertainty that accompany HSCT). Most participants (60%) reported a preference for a peer support intervention prior to the HSCT hospitalization. Despite the limited data on peer support interventions among HSCT recipients and lack of formal peer support experience in most of our cohort, our study shows that HSCT recipients clearly acknowledge the potential benefits of a peer support intervention, and they prefer that it start prior to transplantation.

摘要

同伴支持是一种独特的社会支持形式,患者基于自己的疾病和治疗经历分享情感、社会和实际帮助,对癌症患者的报告结果有积极影响。然而,关于造血干细胞移植(HSCT)受者同伴支持体验的数据有限。我们对 12 名≤6 个月且无任何并发症的异基因 HSCT 受者和 13 名>6 个月且患有慢性移植物抗宿主病的异基因 HSCT 受者进行了半结构化定性访谈。访谈探讨了患者的同伴支持体验以及他们对针对 HSCT 受者需求量身定制的同伴支持干预措施的偏好。尽管大多数(70%)参与者没有正式的同伴支持经验,但大多数(83%)表达了同伴支持的潜在好处的主题(例如,管理 HSCT 伴随的期望和不确定性)。大多数参与者(60%)表示希望在 HSCT 住院前进行同伴支持干预。尽管关于 HSCT 受者的同伴支持干预数据有限,且我们的队列中大多数参与者没有正式的同伴支持经验,但我们的研究表明,HSCT 受者清楚地认识到同伴支持干预的潜在好处,并且他们希望在移植前开始进行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fc2/9119381/c63f6fc5eb93/41409_2022_1711_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验